GOVERNANCE AT THE THRESHOLD · ABOUT ONE MINUTE
The research, at a glance.
The question: Are biotech companies with more investor representatives on their boards at IPO acquired sooner?
THE MAIN FINDING
A 20.7-percentage-point higher investor share of board seats was associated with 1.5× the acquisition rate among companies still at risk. The rounded 95% confidence interval was 1.2–1.9. This is an association, not proof that the directors caused a sale.
THE OWNERSHIP CAVEAT
After adding disclosed investor ownership, the estimate fell to 1.3×. It was significant on the main coding but not robust across reasonable checks. Whether board seats add reliable information beyond ownership remains unestablished.
The scope: 349 North American biotech companies listed in 2015–2021; 99 were acquired by 25 September 2026. These results do not predict an individual company’s sale or establish a cause. Europe is an incomplete, descriptive extension.